The cell cycle and cancer
Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to l...
Gespeichert in:
Veröffentlicht in: | The Journal of pathology 2012-01, Vol.226 (2), p.352-364 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 364 |
---|---|
container_issue | 2 |
container_start_page | 352 |
container_title | The Journal of pathology |
container_volume | 226 |
creator | Williams, Gareth H Stoeber, Kai |
description | Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation. Gene expression profiling of these complex and redundant mitogenic pathways to identify prognostic and predictive signatures and their therapeutic targeting has, however, proved challenging. The cell cycle machinery, which acts as an integration point for information transduced through upstream signalling networks, represents an alternative target for diagnostic and therapeutic interventions. Analysis of the DNA replication initiation machinery and mitotic engine proteins in human tissues is now leading to the identification of novel biomarkers for cancer detection and prognostication, and is providing target validation for cell cycle‐directed therapies. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
doi_str_mv | 10.1002/path.3022 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_907997034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>907997034</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4632-1cffa613139c6562547a0a1e15e793eb889c0f21bcde34c57b23314356d8f9443</originalsourceid><addsrcrecordid>eNp1kD1PwzAQhi0EoqUwMLKgbIgh7dmO7XisCrRIVSmiqBKL5TgXNZB-xa2g_55GKd2YbrjnfXT3EnJNoU0BWGdlN7M2B8ZOSJOClqGOtTwlzf2OhTyiqkEuvP8EAK2FOCcNRrUG4LRJbiYzDBwWReB2rsDALtLA2YXD8pKcZbbweHWYLfL-9DjpDcLhS_-51x2GLpKchdRlmZWUU66dFJKJSFmwFKlApTkmcawdZIwmLkUeOaESxjmNuJBpnOko4i1yV3tX5XK9Rb8x89xXF9kFLrfeaFBaK-AVeV-Trlx6X2JmVmU-t-XOUDBVEaYqwlRF7Nnbg3WbzDE9kn-f74FODXznBe7-N5lxdzI4KMM6kfsN_hwTtvwyUnElzHTUN_rt4_VhGo_NiP8Cg91zyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>907997034</pqid></control><display><type>article</type><title>The cell cycle and cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Williams, Gareth H ; Stoeber, Kai</creator><creatorcontrib>Williams, Gareth H ; Stoeber, Kai</creatorcontrib><description>Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation. Gene expression profiling of these complex and redundant mitogenic pathways to identify prognostic and predictive signatures and their therapeutic targeting has, however, proved challenging. The cell cycle machinery, which acts as an integration point for information transduced through upstream signalling networks, represents an alternative target for diagnostic and therapeutic interventions. Analysis of the DNA replication initiation machinery and mitotic engine proteins in human tissues is now leading to the identification of novel biomarkers for cancer detection and prognostication, and is providing target validation for cell cycle‐directed therapies. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><identifier>ISSN: 0022-3417</identifier><identifier>EISSN: 1096-9896</identifier><identifier>DOI: 10.1002/path.3022</identifier><identifier>PMID: 21990031</identifier><language>eng</language><publisher>Chichester, UK: John Wiley & Sons, Ltd</publisher><subject>Antineoplastic Agents - therapeutic use ; biomarker ; cancer ; cell cycle ; Cell Cycle - physiology ; Cell Cycle Proteins - metabolism ; DNA replication ; DNA Replication - drug effects ; DNA Replication - physiology ; Early Detection of Cancer ; Geminin ; Humans ; MCM ; mitosis ; Neoplasms - drug therapy ; Neoplasms - pathology ; phosphohistone ; Phosphoprotein Phosphatases - metabolism ; Phosphotransferases - metabolism ; Signal Transduction - physiology ; therapy ; Treatment Outcome</subject><ispartof>The Journal of pathology, 2012-01, Vol.226 (2), p.352-364</ispartof><rights>Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4632-1cffa613139c6562547a0a1e15e793eb889c0f21bcde34c57b23314356d8f9443</citedby><cites>FETCH-LOGICAL-c4632-1cffa613139c6562547a0a1e15e793eb889c0f21bcde34c57b23314356d8f9443</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpath.3022$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpath.3022$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,27923,27924,45573,45574</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21990031$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Williams, Gareth H</creatorcontrib><creatorcontrib>Stoeber, Kai</creatorcontrib><title>The cell cycle and cancer</title><title>The Journal of pathology</title><addtitle>J. Pathol</addtitle><description>Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation. Gene expression profiling of these complex and redundant mitogenic pathways to identify prognostic and predictive signatures and their therapeutic targeting has, however, proved challenging. The cell cycle machinery, which acts as an integration point for information transduced through upstream signalling networks, represents an alternative target for diagnostic and therapeutic interventions. Analysis of the DNA replication initiation machinery and mitotic engine proteins in human tissues is now leading to the identification of novel biomarkers for cancer detection and prognostication, and is providing target validation for cell cycle‐directed therapies. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</description><subject>Antineoplastic Agents - therapeutic use</subject><subject>biomarker</subject><subject>cancer</subject><subject>cell cycle</subject><subject>Cell Cycle - physiology</subject><subject>Cell Cycle Proteins - metabolism</subject><subject>DNA replication</subject><subject>DNA Replication - drug effects</subject><subject>DNA Replication - physiology</subject><subject>Early Detection of Cancer</subject><subject>Geminin</subject><subject>Humans</subject><subject>MCM</subject><subject>mitosis</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - pathology</subject><subject>phosphohistone</subject><subject>Phosphoprotein Phosphatases - metabolism</subject><subject>Phosphotransferases - metabolism</subject><subject>Signal Transduction - physiology</subject><subject>therapy</subject><subject>Treatment Outcome</subject><issn>0022-3417</issn><issn>1096-9896</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kD1PwzAQhi0EoqUwMLKgbIgh7dmO7XisCrRIVSmiqBKL5TgXNZB-xa2g_55GKd2YbrjnfXT3EnJNoU0BWGdlN7M2B8ZOSJOClqGOtTwlzf2OhTyiqkEuvP8EAK2FOCcNRrUG4LRJbiYzDBwWReB2rsDALtLA2YXD8pKcZbbweHWYLfL-9DjpDcLhS_-51x2GLpKchdRlmZWUU66dFJKJSFmwFKlApTkmcawdZIwmLkUeOaESxjmNuJBpnOko4i1yV3tX5XK9Rb8x89xXF9kFLrfeaFBaK-AVeV-Trlx6X2JmVmU-t-XOUDBVEaYqwlRF7Nnbg3WbzDE9kn-f74FODXznBe7-N5lxdzI4KMM6kfsN_hwTtvwyUnElzHTUN_rt4_VhGo_NiP8Cg91zyw</recordid><startdate>201201</startdate><enddate>201201</enddate><creator>Williams, Gareth H</creator><creator>Stoeber, Kai</creator><general>John Wiley & Sons, Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201201</creationdate><title>The cell cycle and cancer</title><author>Williams, Gareth H ; Stoeber, Kai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4632-1cffa613139c6562547a0a1e15e793eb889c0f21bcde34c57b23314356d8f9443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic Agents - therapeutic use</topic><topic>biomarker</topic><topic>cancer</topic><topic>cell cycle</topic><topic>Cell Cycle - physiology</topic><topic>Cell Cycle Proteins - metabolism</topic><topic>DNA replication</topic><topic>DNA Replication - drug effects</topic><topic>DNA Replication - physiology</topic><topic>Early Detection of Cancer</topic><topic>Geminin</topic><topic>Humans</topic><topic>MCM</topic><topic>mitosis</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - pathology</topic><topic>phosphohistone</topic><topic>Phosphoprotein Phosphatases - metabolism</topic><topic>Phosphotransferases - metabolism</topic><topic>Signal Transduction - physiology</topic><topic>therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Williams, Gareth H</creatorcontrib><creatorcontrib>Stoeber, Kai</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Williams, Gareth H</au><au>Stoeber, Kai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The cell cycle and cancer</atitle><jtitle>The Journal of pathology</jtitle><addtitle>J. Pathol</addtitle><date>2012-01</date><risdate>2012</risdate><volume>226</volume><issue>2</issue><spage>352</spage><epage>364</epage><pages>352-364</pages><issn>0022-3417</issn><eissn>1096-9896</eissn><abstract>Deregulation of the cell cycle underlies the aberrant cell proliferation that characterizes cancer and loss of cell cycle checkpoint control promotes genetic instability. During the past two decades, cancer genetics has shown that hyperactivating mutations in growth signalling networks, coupled to loss of function of tumour suppressor proteins, drives oncogenic proliferation. Gene expression profiling of these complex and redundant mitogenic pathways to identify prognostic and predictive signatures and their therapeutic targeting has, however, proved challenging. The cell cycle machinery, which acts as an integration point for information transduced through upstream signalling networks, represents an alternative target for diagnostic and therapeutic interventions. Analysis of the DNA replication initiation machinery and mitotic engine proteins in human tissues is now leading to the identification of novel biomarkers for cancer detection and prognostication, and is providing target validation for cell cycle‐directed therapies. Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.</abstract><cop>Chichester, UK</cop><pub>John Wiley & Sons, Ltd</pub><pmid>21990031</pmid><doi>10.1002/path.3022</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-3417 |
ispartof | The Journal of pathology, 2012-01, Vol.226 (2), p.352-364 |
issn | 0022-3417 1096-9896 |
language | eng |
recordid | cdi_proquest_miscellaneous_907997034 |
source | MEDLINE; Wiley Online Library All Journals |
subjects | Antineoplastic Agents - therapeutic use biomarker cancer cell cycle Cell Cycle - physiology Cell Cycle Proteins - metabolism DNA replication DNA Replication - drug effects DNA Replication - physiology Early Detection of Cancer Geminin Humans MCM mitosis Neoplasms - drug therapy Neoplasms - pathology phosphohistone Phosphoprotein Phosphatases - metabolism Phosphotransferases - metabolism Signal Transduction - physiology therapy Treatment Outcome |
title | The cell cycle and cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T18%3A00%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20cell%20cycle%20and%20cancer&rft.jtitle=The%20Journal%20of%20pathology&rft.au=Williams,%20Gareth%20H&rft.date=2012-01&rft.volume=226&rft.issue=2&rft.spage=352&rft.epage=364&rft.pages=352-364&rft.issn=0022-3417&rft.eissn=1096-9896&rft_id=info:doi/10.1002/path.3022&rft_dat=%3Cproquest_cross%3E907997034%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=907997034&rft_id=info:pmid/21990031&rfr_iscdi=true |